HCP-2202 is under clinical development by Hanmi Pharmaceuticals and currently in Phase I for Duodenal Ulcer. According to GlobalData, Phase I drugs for Duodenal Ulcer have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HCP-2202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HCP-2202 is under development for the treatment of unspecified cardiovascular disorders, gastric ulcers and duodenal ulcers. The drug candidate is combination of RLD2202 and RLD2203.
Hanmi Pharmaceuticals overview
Hanmi Pharmaceuticals, a subsidiary of Hanmi Science Co Ltd, develops prescription drugs and over the counter (OTC) drugs. The company’s prescription drugs include antibiotics, antidiarrheal, drugs for osteoporosis, liver supplements and antiemetics. It provides OTC products such as nutritional supplements, calcium supplement, and vitamins, among others. The products of Hanmi Pharmaceuticals are used in the treatment of cancer, depression, dementia, dermatology, diabetes, inflammation, cardiovascular conditions, epilepsy, hepatitis, osteoarthritis, gastrointestinal diseases, obesity, osteoporosis and others. The company operates manufacturing facilities in Hwaseong, Songpa and Pyeongtaek, South Korea. It supplies its products and APIs in various countries in Europe, Asia-Pacific and the Americas. Hanmi Pharmaceuticals is headquartered in Seoul, South Korea.
For a complete picture of HCP-2202’s drug-specific PTSR and LoA scores, buy the report here.